| Project/Area Number |
17K16873
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Obstetrics and gynecology
|
|---|
| Research Institution | Kindai University |
|---|
Principal Investigator |
|
|---|
| Research Collaborator |
MATSUMURA noriomi
|
|---|
| Project Period (FY) |
2017-04-01 – 2019-03-31
|
| Project Status |
Completed (Fiscal Year 2018)
|
| Budget Amount *help |
¥4,160,000 (Direct Cost: ¥3,200,000、Indirect Cost: ¥960,000)
Fiscal Year 2018: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
Fiscal Year 2017: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
|
|---|
| Keywords | 卵巣癌 / がんゲノム / 腫瘍内不均一性 / 癌ゲノム / ゲノム |
|---|
| Outline of Final Research Achievements |
The malignant tumor consists of cancer cells which have various genomic phenotype, that is called intratumor heterogeneity. Almost half of high grade serous ovarian cancer (HGSOC) have disfunction of homologous recombination repair which is one of DNA repair pathway. We have analyzed genomic data of HGSOC to quantify the degree of intratumor heterogeneity and homologous recombination repair deficiency (HRD). We have revealed that intratumor heterogeneity and HRD were associated with prognosis and intratumor heterogeneity was reduced after chemotherapy and HRD score changed throughout time course of treatment in some cases.
|
| Academic Significance and Societal Importance of the Research Achievements |
腫瘍内不均一性が化学療法前後で減少するということは，減少したクローンに化学療法抵抗性の原因が存在することが示唆される．化学療法後のクローンの解析を進めることでHGSOCにおける化学療法抵抗性の原因を明らかにできる可能性がある．また，HRR異常は分子標的治療のバイオマーカーとなり得ることが報告されているが，必ずしも化学療法抵抗性とは関連しないことが示唆される結果であった．初回手術時の腫瘍検体の解析により，分子標的薬が有効と考えられる症例については術後の補助療法としての効果も期待される．
|
